The reemergence of pertussis in the last two decades led to the introduction of adolescents and adults immunization strategies of tetanus-diphtheria-acellular pertussis vaccines (Tdap) in several countries. The health authorities must consider economic aspects when deciding to recommend and fund new programs. Here we present a systematic review of worldwide full economic evaluations of pertussis vaccination targeting adolescents or adults published from 2000. Studies were identified by searching MEDLINE, Excerpta Medica, CRD, and Lilacs databases. Twenty-seven economic evaluations of different strategies with Tdap were identified. Booster vaccination for adolescents and adults were the most frequent, followed by cocooning and pregnant women vaccination. Strategies performance varied considerably among different studies. Assumptions regarding underreporting correction, herd protection and vaccine coverage were crucial to cost-effectiveness results. Understanding the model and the parameters used is essential to understand the results, and identify the major issues important to public health decisions.
Introduction
Pertussis is a highly contagious respiratory disease mainly caused by Bordetella pertussis.
1,2 It causes uncontrollable violent coughing for long periods, most commonly affects infants and young children, and can be fatal, especially in infants up to 6 months of age. 1, 2 Childhood immunization with wholecell pertussis (wP) containing vaccines led to important reduction in pertussis incidence in countries that achieved high vaccine coverage. 2, 3 However, a global reemergence of pertussis has been observed in the last 20 years, in spite of sustained high vaccine coverage. [1] [2] [3] Hypotheses to explain this reemergence are postvaccination waning immunity; reduced effectiveness of acellular vaccines; implementation of molecular methods for diagnosis; improvement of surveillance systems; enhanced disease awareness; and genetic changes in the pathogen. 2 The reemergence of epidemics, severe infections in very young not yet vaccinated infants, and pertussis in older children, adolescents and adults, resulted in renewed attention of the public health authorities to further improve pertussis control and optimize protection through vaccination. 2 Tetanus-diphtheria-acellular pertussis vaccines (Tdap) for adolescents and adults were licensed in 2005 and additional immunization strategies were proposed: 1) booster doses for adolescents and adults; 2) cocooning strategy; 3) pregnant women and post-partum maternal vaccination; and 4) vaccination of healthcare workers. 2 Pertussis among infants frequently presents as severe cases, with higher hospitalization and case-fatality rates. [4] [5] [6] Cocooning and pregnant women vaccination aim to avoid pertussis among infants aged less than one year, particularly infants younger than two months, who have not received any vaccine dose. Cocooning strategy is vaccinating neonates' contacts, potentially reducing household transmission and preventing infant infection. Pregnant women vaccination results in direct newborn protection through transplacental antibody transfer from mother to infant. [7] [8] [9] Even though the health benefits of some of these pertussis vaccination strategies have been demonstrated, 7, 8, 10, 11 national health authorities must also consider economic aspects when deciding to recommend and fund new programs. Economic evaluation of vaccination programs may support decisionmaking, and is considered an essential tool in a context of rising budget constraints. 12 Health economic evaluation depends on good quality data of the disease epidemiology, not easily available in this case. Pertussis burden is underestimated by the surveillance systems, due to limited demand/access to healthcare, cases' underrecognition or misdiagnosis, and underreporting.
Results

Search results
The initial searches identified 1,318 articles. After duplicates removal and the titles and abstracts reading, 33 studies were considered potentially relevant and retrieved in full text. After reading the full text, 27 studies met the eligibility criteria and were included in this review (Figure 1 ). Table 1 describes the methodological characteristics of economic evaluations of pertussis immunization programs for adolescents and adults. Most studies considered developed countries: 12 in the United States of America, four in the Netherlands, three in Canada, two in England, and one each in Australia, Germany, Italy, Japan, and Spain. Only one referred to a developing country (Brazil).
Methodological studies characteristics
The studies evaluated 7 different strategies involving Tdap vaccine: 1) adolescents vaccination; 2) adults vaccination; 3) healthcare workers vaccination and its impact on hospital outbreak control; 4) cocooning; 5) pregnant women vaccination; 6) postpartum maternal vaccination; and 7) adults with chronic obstructive pulmonary disease. Adolescents and adults immunization were the most frequent strategies evaluated: 11/27 each. The adults vaccination strategies were: one-time vaccination at 20 to 64 years of age (8/11) , decennial boosters (6/11), and vaccination at 65 years of age or older (2/11). Six studies evaluating adolescents' immunization were published from 2002 to 2005.
The economic evaluations of Tdap considered different strategies as cocooning: vaccinating both parents immediately after birth; or assuming that fathers would be vaccinated during the pregnancy and mothers would be vaccinated immediately after delivery; or vaccinating mothers and another adult caregiver after birth; or vaccinating mothers immediately after birth and all other close contacts before the birth; or vaccinating both parents and other close contacts during pregnancy or immediately after delivery.
The first study evaluating pregnant women immunization was published in 2010. This strategy and cocooning were the most frequent strategies evaluated since then (7 studies each), followed by adult immunization (6), adolescents (4), postpartum maternal vaccination (3), and health professionals (1) .
Ten studies used dynamic models, which were more frequently used to evaluate adolescents vaccination (6), followed by adults vaccination (4), cocooning (2), pregnant women (2), and health professionals vaccination (1) . Thirteen studies used static models: seven used Markov, and six used decision tree. Most of them evaluated cocooning, and/or adults vaccination (6 each), followed by pregnant women vaccination (4), adolescents (3), postpartum maternal vaccination (2), and health professionals (1). Three papers did not report the model used and one used cohort simulation.
Vaccines and vaccination programs assumptions
Vaccines and vaccination programs data are presented in Table 2 .
Ten studies that evaluated adolescents or adults vaccination considered vaccine coverage >50%, six of them considered >80%. Coverage varied from 20 to 96%, for cocooning, and from 57 to 96%, for pregnant women vaccination.
Ten studies clearly stated they incorporated herd protection in the model. Among them, six evaluated adolescent immunization, seven adult immunization, three cocooning, one pregnant immunization, one postpartum maternal immunization. Seven studies that evaluated adolescents and/or adults strategies did not consider herd protection.
Three studies used Markov model to evaluate adolescent and adult vaccination and considered herd protection applying a reduction factor on pertussis incidence in unvaccinated infants and adults or in the base case analysis. Caro et al. used a cohort simulation to evaluate adolescent vaccination and considered indirect impact on other age groups and on unvaccinated adolescents. Four studies that used dynamic models did not clearly state they incorporated herd protection in the model.
McGarry et al. used a dynamic model age-structured with compartments repeated for each month of age below 1 year and 1-year age groups from 1 to 99 years old. This model made possible evaluate a Tdap vaccination of adults aged 65 years in addition to DTaP vaccination from age 2 months to 4-6 years, and one dose of Tdap once to individuals 11-64 years of age in place of the decennial Td booster.
Studies that evaluated pregnant women immunization made different assumptions regarding efficacy of maternal antibodies in infant protection and duration of protection of maternal antibodies (Table 2 ). One study considered that 60% of maternal antibodies would pass through placenta. Duration of maternal antibodies protection was assumed as two months, three months, four months and six months. Just one study considered interference of maternal antibodies in the infant response to active pertussis vaccination, assuming a negative impact (10% reduction) in the infant responses to the second and third vaccine doses.
Fourteen studies included adverse events following immunization in the model ( Table 2) . Just three studies considered vaccine wastage rate in the model, assumed as 15%, 10% and 5%. Table 3 shows pertussis incidence estimates used in the studies. Pertussis incidences among adolescent or adults were considered in 20 of 27 studies, and 18 of them used some strategy to correct pertussis underreporting.
Epidemiological estimates
Ten studies used official incidence data multiplied by a correction factor, which varied from 2.5 to 660; four studies considered a range of incidences for adults or adolescents; and four studies derived pertussis incidence from local studies data. The approaches for estimating pertussis incidences among adolescents and adults and the correction factor were based on serological surveys (8 studies), clinical trials (6), authors' assumption (2), capture-recapture studies (1), enhanced surveillance (1), and compilation of data from previous dTpa economic studies (1) . One study applied the infants' disease incidence to women of childbearing age. Lee et al. (2005) estimated the burden of disease among adolescents and adults in the USA based on 2003 Massachusetts State incidence data. Massachusetts was the only state in the USA that had a single-serum enzyme-linked immunosorbent assay for IgG anti-pertussis toxin available as a diagnostic test, which allows enhanced disease detection among adolescents and adults. Two studies corrected disease data for infants to take underreporting into account, using an underreporting factor of 2 and 1.15.
Pertussis incidence rates varied from 22 to 435 per 100,000, for infants, from 10 to 511 per 100,000, for adolescents, and from 5.33 to 2,606 per 100,000, for adults.
Supplementary Table 1 shows outpatient cases, hospitalizations, complications and case-fatality rates estimates. Even after correcting underreporting, most studies considered that all pertussis cases among adolescents and adults use health care services, resulting in cost. Among adolescents and adults, mild outpatient cases varied from 1% to 79.3%, while severe cases ranged from <1% to 66%. Caro explored the impact of including asymptomatic infections in the disease transmission dynamic model.
Cost estimates
The elements of costs considered in the reviewed studies are described in Supplementary Seven studies that evaluated strategies focused on protecting infants (pregnant women vaccination, maternal postpartum vaccination or cocooning) considered caregivers loss of productivity. Table 4 shows the summary measures presented in the results of the analyses.
Results of the analyses
Two studies showed that adolescents' vaccination strategy was cost-saving at society perspective. Other seven studies had incremental cost-effectiveness ratio considered cost-effective or highly cost-effective and recommended it as a good strategy. Adolescent vaccination presented unsatisfactory results in only one study.
Among 11 studies that evaluated adults vaccination strategy, the program was considered cost-effective in six and costsaving in two.
Cocooning strategy performance diverged among studies. It was cost-saving in two studies, and not cost-effective in the other studies, with ICER ranging from U$112,091/QALY to U $2,005,940/QALY.
Seven studies evaluated pregnant women vaccination and the ICER varied from cost-saving to not cost-effective (US$ 439,708.46/QALY). When compared with cocooning, pregnant women vaccination had better economic performance in four of five studies.
Ten studies declared sponsorship by pharmaceutical industry; eleven by public institutions and six did not report sponsorship. All studies sponsored by pharmaceutical industry showed good results for Tdap vaccination, except two that evaluated cocooning, pregnant women and elderly vaccination. All cost-saving studies were in this group.
All studies conducted some Sensitivity Analyses (Supplementary Table 3 ). The parameters with the greatest impact on the results were pertussis incidence, followed by vaccine efficacy and vaccine price.
Discussion
The first Tdap economic evaluation was published in 2002, when a significant increase in pertussis incidence among unvaccinated infants, adolescents and adults became a problem in developed countries and new immunization strategies for older age groups became available. 14, 41 Adolescents and adults vaccination were the first strategies introduced in developed countries, such as Australia, Canada, France, Germany and the USA, 2 and also the first economically evaluated.
In general, the studies found favorable cost-effectiveness ratio for adolescents and adults vaccination, particularly for adolescents' vaccination. Assumptions regarding underreporting correction, herd protection and vaccine coverage were crucial to cost-effectiveness results of adolescents and adults vaccination. In general, pertussis is considered a childhood disease and goes unnoticed among adolescents and adults. Adolescents and adults usually have milder symptoms, similar to viral infections, making pertussis diagnosis difficult. 42, 43 Mostly, only culture-positive cases or cases with typical symptoms are reported. Underreporting is an issue since asymptomatic infections are transmissible. 5, 43 Most studies on the cost-effectiveness of adolescent and adults vaccination explicitly took underreporting into account, increasing the incidence detected by regular health surveillance from 2.5 to 600 times. Serological surveillance studies, capture-recapture studies, enhanced surveillance data and author assumption were the source for correction factor. Increasing the incidence has a positive impact on the performance of the strategies evaluated. 17, 19, 20, 26, 28 Some studies considered that all pertussis cases used health services resulting in direct costs. Assuming that undiagnosed or unreported cases are just as severe and costly as reported cases probably overestimates pertussis-related health resource utilization and costs. Few studies considered asymptomatic cases and recognized their importance in the transmission of the disease. 24, 26, 28, 34, 35 Eleven studies that evaluated adolescents or adults vaccination considered herd protection. 14, 17, 19, 20, 22, 24, 26, 28, 29, 35, 38 Eight of them used dynamic models and three studies used static models and included herd protection as a correction factor. Herd protection refers to protection of susceptible individuals due to decreased transmission of the pathogen, i.e., reduction in the force of infection, when a high proportion of the population is immunized. Dynamic models allow projecting changes in transmission patterns, taking herd protection into account. Adolescents and adults are the main source of pertussis infection for infants. 2, 4, [44] [45] [46] [47] [48] Considering herd protection for adolescents and adults vaccination would result in averted cases among infants. However, recent studies showed the lack of sterilizing mucosal immunity following aP vaccination. 49 The vaccinated could be colonized by Bordetella pertussis and transmit the disease, lacking herd protection of adolescents and adults vaccination. 49 Some economic evaluations of adolescents and adults vaccination overestimated vaccine coverage, reaching 96%, which contributed to the good performance of the program. Vaccination coverage among adolescents and adults is low for many vaccines in most countries. In the USA, Tdap vaccine coverage among adults aged 19-64 years was 24.7%, in 2014-2015. 50 According to the Vaccine European New Integrated Collaboration Effort consortium, adult vaccination coverage for tetanus and diphtheria ranged from 61% to 74%, in 2010-2011. 51 In Brazil, dT coverage among adults is approximately 33% per year (Immunization Division, São Paulo State) and Tdap coverage among pregnant women was 40.3%, in 2015.
The primary objective of the cocooning and pregnant women vaccination is to reduce transmission to infants. The first economic study of cocooning was published in 2004. 15 Cocooning was introduced in developed countries, such as Australia, France, Germany and the USA, in the early 2000s. 2 This review showed that cocooning performance diverges among studies. The economic evaluations with higher effectiveness for cocooning, 23, 33 even to the point of costsaving, 24 assumed that the mother was the only source of pertussis for the infants, overestimating the impact of postpartum maternal vaccination.
Cocooning effectiveness/impact also diverged among different studies, and there is evidence that the strategy is inefficient to reduce hospitalizations and deaths among infants in settings with low pertussis incidence. In Canada, it would be necessary to vaccinate more than 10,000 people to prevent one hospitalization, and vaccinate at least 1 million to prevent one death of infant <1 year of age, in a setting with 57 hospitalizations per 100,000 inhabitants and risk of parentsto-infant transmission of 35%. 52 In the USA, a study of a postpartum vaccination program did not show any beneficial effect. 53 After a frustrating performance of the previous strategies, pregnant women vaccination was introduced in USA, in 2011, and UK, in 2012. The first economic evaluation was published in 2010, when many countries reported further increase of pertussis incidence in infants. 3, 54, 55 Pregnant women vaccination was demonstrated efficacious, had good economic performance and became the main strategy of adults' pertussis vaccination to protect infants.
The overall impact and cost-effectiveness of cocooning are likely to be substantially lower than pregnant women vaccination, which requires only one dose, whereas cocooning requires, as a minimum, multiple doses for parents and family members. Implementing an effective cocooning strategy with high coverage has also proved challenging in several countries. 2 Pertussis incidence was one of the parameters that mostly influenced the results of pregnant women vaccination programs. Westra et al. (2010) 25 reported that ICERs increased 6x and 3x for cocooning and pregnant women vaccination, respectively, when unreported cases were not taken into account in the analysis. Van Hoek et al. 40 show that pregnant women pertussis immunization would be highly cost effective if the peak incidence of infant disease at the time the program was introduced continues (ICER~17,000 during incidence peak). However, the ICER was highly dependent on the future incidence of pertussis in infants under 3 months of age and it will vary over time considering the cyclical pattern of the disease. 40 The number of vaccinees in cocooning and pregnant women vaccination does not allow the development of herd protection and static models are adequate to evaluate these strategies. 25, 39 Only eight studies included the public health response in the direct costs. [17] [18] [19] 21, 27, 32, 36, 39 In one study in the USA, the epidemiological investigation of household contacts, laboratory testing the symptomatic contacts and antibiotic treatment for contacts positive for B. pertussis cost US$2,269/case, being an important component of costs. 32 Another study, in Brazil, estimated that surveillance costs per case were higher than the outpatient care costs per case. 39 Many countries have longstanding surveillance systems for pertussis. 56 The case reporting results in a public health response, including cases interviews, contacts testing (PCR or culture), identification of symptomatic contacts, and treatment of symptomatic contacts or chemoprophylaxis for all contacts. The U.S. Centers for Disease Control and Prevention recommends post exposure prophylaxis for all household contacts of a pertussis case. 57 In Brazil, the MoH recommends nasopharyngeal swab for diagnostic tests for all domiciliary contacts of pertussis cases. 58 The contact tracing results in costs that should be considered in economic evaluation of pertussis vaccination programs.
Just one study referred to a developing country. 54 Pregnant women vaccination was shown a cost-effective intervention for preventing pertussis cases and deaths in infants in Brazil. Brazil, Argentina and Chile reported significant increase in pertussis incidence rates in recent years, despite pertussis childhood vaccination with whole-cell vaccines and have already introduced pregnant women vaccination with Tdap. 3, 54 This systematic review and synthesis of the results of the articles included in the analysis of economic evaluations of pertussis vaccination strategies in adults presented more challenges than usual in this type of study due the large number of different strategies, and methodological differences of the studies. The strategies performance and economic evaluation conclusions varied considerably among different studies. Variations were due to different assumptions on epidemiological parameters, health service utilization and costs made in the studies from different countries. Understanding the model and all the parameters used in the economic analysis is essential to understand the results, and identify the major issues important to public health decisions.
Methods
Protocol and registration
This systematic review has been conducted based on the Centre for Reviews and Dissemination (CRD) guidelines 12 . A protocol was developed before initiating this review but it was not registered in the international prospective register of systematic reviews (PROSPERO).
Literature search
A search of studies published from January 1st, 2000 to July 15th, 2016 was conducted in four databases: MEDLINE (via PubMed), Excerpta Medica, CRD and Latin-American and Caribbean Health Sciences Literature (LILACS). It was deemed appropriate to narrow the search to this timeframe because Tdap was licensed in 2005.The following terms were used: 'pertussis' and 'pertussis vaccine' in combination with any of the following: 'economics', 'pharmaceutical', 'cost analysis', 'cost of illness', 'cost(-) benefit', 'health care cost", 'cost(-) effectiveness', 'cost(-)utility', 'cost' and/ or (pharmaco) economic evaluation. The search was limited to full economic evaluations on pertussis vaccination of adolescents (≥10 years of age) and adults. The Appendix 1 shows the electronic search strategies created for each database.
Searching other sources
The reference lists of all included studies identified in the electronic databases were reviewed to identify further studies.
Eligibility criteria
The eligibility criteria were defined based on the components of the PICOS approach:
• Population: adolescents (≥10 years of age) and adults (including healthcare workers, pregnant women, cocooning and any other vaccination strategies targeting adolescents or adults); • Intervention: pertussis vaccination;
• Comparators: no vaccination and strategies of pertussis vaccination of adolescents and adults; • Outcome: incremental cost-effectiveness ratio (ICER) or cost-benefit ratio; • Study design: full economic evaluation, defined as a comparative analysis of costs and consequences of two alternative healthcare interventions; including costminimization analysis, cost-effectiveness analysis, costutility analysis, and cost-benefit analysis.
Study selection
One reviewer (EGF) screened all titles and abstracts of studies retrieved by the search and selected them using the eligibility criteria. Any doubts during this process were resolved by discussion with another reviewer (PCS).
Data extraction
A predefined data extraction form was calibrated amongst the two reviewers (EGF and CCMR) using a random sample of five included studies. After this, data was independently extracted by the two reviewers (EGF and CCMR) and checked by them. The divergences between the data that the reviewers extracted were resolved by discussion or by arbitrage of a third reviewer (PCS).
Data collected
• Methodological characteristics: type of study, perspective, model, herd protection, time horizon, number of cohorts, currency and year of costs, discount rate, sensitivity analysis, and parameters varied in the sensitivity analysis; • Estimates of key parameters: epidemiological data (pertussis incidence, disease severity, and case fatality rate); vaccine related data (vaccination schedule, coverage, efficacy, adverse events, and waning immunity rate); costs (direct and indirect), and summary measures (incremental cost-effectiveness ratios (ICERs) or cost-benefit ratio); • Research funding sources.
To improve comparability between studies results, all summary measures presented in different currencies were adjusted to 2016 value (latest price year used in included studies) using consumer price index [59] . Afterwards, they were converted to international dollar units using Purchasing Power Parity (PPP), the exchange-rate equivalent to an identical basket of goods and services in countries (Organization for Economic Co-operation and Development. 60 
Synthesis of results
The more relevant results were summarized as a narrative synthesis. The methodological characteristics and key variables estimates are shown in summary tables.
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